Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Panitumumab a novel drug in cancer treatment Carteni G; Fiorentino R; Vecchione L; Chiurazzi B; Battista CAnn Oncol 2007[Jun]; 18 Suppl 6 (ä): vi16-21The epidermal growth factor receptor (EGFR) is a member of the erbB family overexpressed in most of the solid tumors. In cancer cells, the overexpression of EGFR correlates with the development and the progression of tumor. Panitumumab is a fully human monoclonal antibody that blocks the extracellular domain of the EGFR and has not been associated with the formation of any antibodies directed against it. This review summarizes on the preclinical and clinical development of panitumumab in human solid tumors. As bevacizumab and cetuximab have been approved for colorectal cancer because of their improvements in progression-free survival and overall survival when associated with chemotherapy, panitumumab represents an interesting molecule which needs more phase III studies to validate its efficacy.|Animals[MESH]|Antibodies, Monoclonal/adverse effects/*therapeutic use[MESH]|Antineoplastic Agents/adverse effects/*therapeutic use[MESH]|Colorectal Neoplasms/*immunology/metabolism/*therapy[MESH]|ErbB Receptors/antagonists & inhibitors/biosynthesis/genetics/immunology[MESH]|Humans[MESH]|Mice[MESH]|Panitumumab[MESH] |